Ginkgo Bioworks (US.DNA)
资本配置审计 · 期间： 2019 – 2026
核心指标
US.DNA · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 105.0% | → |
| ROE | -30.8% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.96 | ↓ |
| Gross Margin | 87.8% | → |
US.DNA (Ginkgo Bioworks) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 105.0% → ROE -30.8% ↓ Cash Conversion - → D/E Ratio 0.96 ↓ Gross Margin 87.8% →
核心指标
US.DNA (Ginkgo Bioworks) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 105.0% →ROE -30.8% ↓Cash Conversion - →D/E Ratio 0.96 ↓Gross Margin 87.8% →免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies